4-(Azaniumylmethyl)-5-(hydroxymethyl)-2-methylpyridin-3-olate

Base Information

• Chemical Name: 4-(Azaniumylmethyl)-5-(hydroxymethyl)-2-methylpyridin-3-olate
• CAS No.: 85-87-0
• Molecular Formula: C8H12 N2 O2
• Molecular Weight: 168.195
• Hs Code.: 2933399090
• Mol file: 85-87-0.mol

Synonyms:

Chemical Property of 4-(Azaniumylmethyl)-5-(hydroxymethyl)-2-methylpyridin-3-olate

Chemical Property:

• Vapor Pressure: 2.92E-09mmHg at 25°C
• Melting Point: 193-193.5 °C
• Boiling Point: 460.1°C at 760 mmHg
• PKA: 9.98±0.10(Predicted)
• Flash Point: 232.1°C
• PSA: 79.37000
• Density: 1.282g/cm³
• LogP: 0.74690
• Storage Temp.: Hygroscopic, Refrigerator, under inert atmosphere
• Solubility.: DMSO (Slightly), Methanol (Slightly)
• XLogP3: -0.4
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 3
• Rotatable Bond Count: 2
• Exact Mass: 168.089877630
• Heavy Atom Count: 12
• Complexity: 143

Purity/Quality:

99% ^*data from raw suppliers

4-(Aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC1=NC=C(C(=C1[O-])C[NH3+])CO

Technology Process of 4-(Azaniumylmethyl)-5-(hydroxymethyl)-2-methylpyridin-3-olate

There total 33 articles about 4-(Azaniumylmethyl)-5-(hydroxymethyl)-2-methylpyridin-3-olate which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 100.0%

pyridoxamine dihydrochloride (524-36-7) → pyridoxamine (85-87-0)

Guidance literature:

With sodium hydroxide; In water; pH=9;

Reference yield:

D-Fructose (57-48-7,18875-34-8) + L-leucine (61-90-5,21675-61-6,25248-98-0,70-45-1) → pyridoxamine-5'-phosphate (529-96-4) + pyridoxal 5'-phosphate (54-47-7) + pyridoxal (66-72-8) + pyridoxamine (85-87-0)

Guidance literature:

With air; ATCC 38399 h^- leu1-32; In various solvent(s); at 30 ℃; for 36h; pH=4.5; Further Variations:; Reagents; reaction times; Product distribution; Microbiological reaction;

DOI:10.1271/bbb.65.1789

Reference yield:

D-Glucose (2280-44-6) + L-leucine (61-90-5,21675-61-6,25248-98-0,70-45-1) → pyridoxamine-5'-phosphate (529-96-4) + pyridoxal 5'-phosphate (54-47-7) + pyridoxal (66-72-8) + pyridoxamine (85-87-0)

Guidance literature:

With air; ATCC 38399 h^- leu1-32; In various solvent(s); at 30 ℃; for 36h; pH=4.5; Further Variations:; Reagents; reaction times; Product distribution; Microbiological reaction;

DOI:10.1271/bbb.65.1789

upstream raw materials:

2-Methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine oxime

pyridoxine triacetate

Glutamic acid

pyridoxal

Downstream raw materials:

pyridoxal

C₂₀H₂₄N₂O₄

2-aminophenylacetic acid tert-butyl ester

(8-Methyl-2-phenyl-4H-pyrido[4,3-e][1,3]oxazin-5-yl)-methanol

Refernces

N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation

10.1016/j.bmc.2009.02.018

The research focuses on the development and evaluation of N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal (MG) scavengers to inhibit advanced glycation endproduct (AGE) formation. The purpose of this study was to address the issue of non-enzymatic glycation of proteins, which leads to the formation of AGEs that are associated with various age-related diseases and complications, including diabetes. The researchers synthesized N-terminal Dap peptides and assessed their ability to prevent protein modifications by MG, a highly reactive α-dicarbonyl compound. The peptides demonstrated a high scavenging potency, as evaluated through various assays including RP-HPLC, SDS–PAGE, and cell viability studies, and were compared to known AGE inhibitors such as aminoguanidine, pyridoxamine, metformin, and carnosine. The study concluded that N-terminal Dap containing dipeptides effectively inhibit the formation of AGEs and may provide a therapeutic potential for decelerating and treating AGE-related diseases. Chemicals used in the process included Dap and various amino acids to synthesize the peptides, as well as MG and other α-dicarbonyl compounds for the assessment of scavenging activity.